Real World Retina: Challenges in the Management of Retinal Diseases—Focus on DME and DR
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.
Overview
Provider Statement
This continuing education activity is provided by 
Support Statement
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.
Activity Description
Pinnacle clinical studies utilizing intravitreal anti-vascular endothelial growth factor (VEGF) therapies for the management of retinal diseases have demonstrated significant visual and anatomical improvements. However, translating these promising results into real-world practice does not always result in comparable outcomes to clinical studies due to undertreatment and loss of patient adherence because of treatment burden. New and emerging therapies with extended durations of action along with the refinement of personalized treatment protocols are helping to address treatment burden, while baseline factors and imaging techniques that assist with monitoring of therapy response have the potential to optimize visual and anatomical outcomes. In this monograph, experts in the field evaluate the evidence for anti-VEGF treatment outcomes for diabetic macular edema (DME) and diabetic retinopathy (DR) in clinical practice, identify prognostic indicators for predicting anti-VEGF therapy outcomes, and assess the latest evidence regarding safety, efficacy, and durability of new therapies for the management of DME and DR.
Target Audience
The intended audience for this activity is retina specialists, ophthalmologists, and other healthcare professionals involved in the management of patients with retinal disorders.
Learning Objectives
Upon successful completion of this activity, participants should be better able to:
- Evaluate the evidence for anti-VEGF treatment outcomes in diabetic macular edema in clinical practice.
- Identify prognostic indicators for predicting anti-VEGF therapy outcomes in patients with DME.
- Assess the latest evidence about new treatments for DME, including their safety, efficacy, and durability.
- Evaluate the evidence for anti-VEGF treatment outcomes in DR in clinical practice.
- Identify relevant patient baseline factors for predicting anti-VEGF therapy outcomes in patients with DR.
- Assess the applicability of recent advances in imaging for monitoring treatment response in patients with in DR.
Activity Co-Chairs
Diana V. Do, MD
Vice Chair for Clinical Affairs
Professor of Ophthalmology
Byers Eye Institute
Stanford University School of Medicine
Palo Alto, CA
Yasha Modi, MD
Associate Professor of Ophthalmology
New York University
New York, NY
Faculty
Mark R. Barakat, MD
Director of Retinal Research Institute
Retinal Consultants of Arizona
Clinical Assistant Professor of Ophthalmology
University of Arizona College of Medicine – Phoenix
Phoenix, AZ
W. Lloyd Clark, MD
Palmetto Retina Center, LLC
Assistant Clinical Professor of Ophthalmology
University of South Carolina School of Medicine
Columbia, SC
Jennifer I. Lim, MD, FARVO, FASRS
Professor of Ophthalmology
Marion H. Schenk Chair and UIC Distinguished Professor of Ophthalmology
Director of the Retina Service
Vice-Chair for Diversity and Inclusion
Department of Ophthalmology
University of Illinois College of Medicine at Chicago
Chicago, IL
Christina Y. Weng, MD, MBA
Professor of Ophthalmology
Fellowship Program Director, Vitreoretinal Diseases & Surgery
Baylor College of Medicine
Houston, TX
Medical Writer
Valerie Zimmerman, PhD
Planner/Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Accreditation
In support of improving patient care, Vindico Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation
Vindico Medical Education designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This enduring material is approved for 1 year from the date of original release, December 30, 2023, to December 29, 2024.
How to Participate in This Activity and Obtain CE Credit
To participate in this activity, you must read the objectives, answer the polling and pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 7 of the 10 posttest questions correctly. If a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ certificate.
Disclosures
Vindico Medical Education adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a continuing education activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Relationship information is accurate at the time of content development.
The articles in this monograph were composed by medical writer Valerie Zimmerman, based on the presentations of Drs. Barakat, Clark, Do, Lim, Modi, and Weng during live symposiums held on September 12 and 20, 2023. The monograph has been approved by each of the faculty individually as an accurate representation of their presentations.
Activity Co-Chairs and Faculty report the following relevant financial relationship(s)
Mark R. Barakat, MD
Consultant: AbbVie, Adverum, Alcon, Alimera, Allegro, Allergan, Annexon, Apellis, Arctic Vision, Bausch + Lomb, Biogen, CalciMedica, Clearside, Coherus, EyePoint, Genentech, IVERIC bio, Kodiak, Novartis, Ocular Therapeutix, Opthea, Outlook Therapeutics, Palatin Technologies, Regeneron, Regenxbio, RevOpsis, Roche, Stealth Biotherapeutics
Speaker Contracted by Ineligible Company: Apellis, Bausch + Lomb, Genentech, IVERIC bio, Novartis, Regeneron
Independent Research Contractor: Adverum, Annexon, CalciMedica, Clearside, EyePoint, Gemini, Genentech, Gyroscope, Kodiak, Novartis, Ocular Therapeutix, Oculis, Opthea, Oxular, Oxurion, Regenxbio, ReNeuron, Ribomic, Roche, Stealth BioTherapeutics, Unity Biotechnology
Individual Stocks and Stock Options: NeuBase, Oxurion, RevOpsis
W. Lloyd Clark, MD
Advisor: Bayer, Genentech/Roche, Regeneron
Consultant: Bayer, Genentech/Roche, Regeneron
Speaker Contracted by Ineligible Company: Genentech/Roche, Regeneron
Independent Research Contractor: Bayer, Genentech/Roche, Kodiak, Regeneron
Diana V. Do, MD
Consultant: Allergan, Apellis, Biogen, Boehringer Ingelheim, IVERIC bio, Kodiak, Regeneron
Independent Research Contractor: Boehringer Ingelheim, Regeneron, Regenxbio
Individual Stocks and Stock Options: Kodiak
Jennifer I. Lim, MD, FARVO, FASRS
Advisor: Alimera, EyePoint, Regeneron
Consultant: Alimera, Aura, Cognition, Eyenuk, EyePoint, Genentech, IVERIC bio, Luxa, Opthea, Quark, Regeneron, Santen, Unity, Viridian
Speaker Contracted by Ineligible Company: IVERIC bio
Independent Research Contractor: Adverum, Aldeyra, Eyenuk, Genentech, Janssen, NGM, Regeneron, Regenxbio, Spring Vision
Yasha Modi, MD
Consultant: AbbVie, Alcon, Apellis, DORC, EyePoint, Genentech, IVERIC bio, Notal Vision, Regeneron, Thea, Zeiss
Christina Y. Weng, MD, MBA
Consultant: Alcon, Alimera, Allergan/AbbVie, DORC, EyePoint, Genentech, IVERIC bio, Novartis, Regeneron, Regenxbio
Independent Research Contractor: Alimera, AGTC, DRCR Retina Network
Medical Writer reports the following relevant financial relationship(s)
Valerie Zimmerman, PhD
No relevant financial relationships to disclose.
Planner/Reviewer reports the following relevant financial relationship(s)
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.
Vindico Medical Education staff report the following relevant financial relationship(s)
No relevant financial relationships to disclose.
Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Unlabeled and Investigational Usage
The audience is advised that this continuing education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2023 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any Vindico Medical Education continuing education activity does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the FDA. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CE Questions?
Contact us at cme@vindicoCME.com